Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03708263
Other study ID # 2017_57
Secondary ID 2018-A01904-51
Status Terminated
Phase N/A
First received
Last updated
Start date September 8, 2020
Est. completion date September 14, 2021

Study information

Verified date February 2022
Source University Hospital, Lille
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Rosacea is a frequent dermatological condition, with a chronic and disturbing evolution that is characterized by redness, permanent erythema associated with telangiectasia (visible and permanent dilatation of the small vessels). It frequently affects men and women with fair skin and can have significant psycho-emotional consequences. To counteract the unaesthetic appearance of redness and eliminate telangiectasia, the use of the laser is proposed to the patient. This study is a single center prospective, randomized, controlled split face study to compare 532nm KTP laser versus 585 nm PLV Laser in terms of improvement of the symptoms in the treatment of Erythematotelangiectatic Rosacea 20 subjects will receive up to 3 laser treatments at day 0, month 2 and 4 and will be followed at month 6 and 12.


Description:

Adult male and female subjects 18 years of age or older will participate in the study after the objectives, methods, and potential risks of the study have been explained, and after they have signed the informed consent form. Patients will come to the investigation center for a maximum of 6 visits.


Recruitment information / eligibility

Status Terminated
Enrollment 1
Est. completion date September 14, 2021
Est. primary completion date September 14, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Fitzpatrick Skin Type I - III - Post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrolment and during the entire course of the study. - Clinical diagnosis of Erythematotelangiectatic Rosacea stade II - Homogeneous extend and staining telangiectasia in each half face - Patient never treated with laser for Rosacea - Patient doesn't wish to use systemic corticosteroids or retinoids; or topical corticosteroids or retinoids on the treated area. - Patient agreeing to have limited exposure to the sun and use of a protective screen (index 50 or higher) every day of the study and throughout its duration if it takes place from May to September. - Patient must be able to read, understand and sign the Informed Consent Form - Patient able to adhere to the program of visits of the study and the other imperatives of the protocol - Patient accepting to have photographs taken on the face - Quality of social insurance or social security entitlement Exclusion Criteria: - Pregnant and/or breastfeeding woman or childbearing age without effective contraception - Alcohol abuse assessed at the discretion of the investigator - History of prior laser or light based procedures for any other pathology for the face within 6 months of study participation Fitzpatrick Type IV à VI - Systemic use of isotretinoin in the 6 months prior to inclusion in the study. - Topical use of retinoids and / or corticosteroids in the 4 weeks prior to inclusion in the study. - Patient under photo sensitization treatment - Patient suffering from significant concurrent illness such as type 1 diabetes, cardiovascular disease, uncontrolled hypertension, neurological disease, lupus erythematosus, scleroderma. - Patient subject to hypertrophic or abnormal scarring - Patient presenting or having a malignant tumor or skin cancer in the area to be treated. - Having a known anticoagulative condition or taking prescription anticoagulation medications. - Participation to another clinical study involving a laser or drug within three months of inclusion in the study. - Smoker or former smoker in the 12 months prior to inclusion in the study. - Patient with excessive tattoos in the area to be treated and / or wishing to tattoo the treated area during the study. - Patient treated for cancer by chemotherapy or radiotherapy - Patient with hyper or hypo pigmentation - Patient unable to understand protocol or give consent - Legal incapacity (persons deprived of their liberty or under guardianship or curatorship) - Patient in emergency or in detention - Clinical follow-up impossible for psychological, family matters, social or geographical reasons

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Excel V 532nm (KTP) green Laser
Each subject's face will be divided in half and labeled as A (Right Side of the Face) or B (Left Side of Face). The allocation of active comparator and experimental treatment arms will be determined by randomization
PHOTOLASE PLV 585 nm yellow laser
Each subject's face will be divided in half and labeled as A (Right Side of the Face) or B (Left Side of Face). The allocation of active comparator and experimental treatment arms will be determined by randomization

Locations

Country Name City State
France Hop Claude Huriez Chu Lille Lille

Sponsors (3)

Lead Sponsor Collaborator
University Hospital, Lille Institut National de la Santé Et de la Recherche Médicale, France, Medical Research Fund of the Tampere University Hospital, Finland

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Degree of improvement in Erythematotelangiectatic Rosacea Measured, for each treatment arm, based on blinded physician assessment of subject photographs using the 7 points Telangiectasia Grading Score.
(-1 = Aggravation of telangiectasia, 0 = no change, 1 = poor improvement (<25% decrease), 2 = intermediate improvement (25-50% decrease), 3 significant improvement (50-75% decrease), 4 = very significant improvement (75-99% decrease), 5 = complete improvement (100% decrease)
at Month 2
Secondary Degree of improvement in Erythematotelangiectatic Rosacea evaluated by a blinded physician. Measured, for each treatment arm, based on subject photographs using the 7 points Telangiectasia Grading Score at Month 4, 6,12
Secondary Measures of skin reaction for each treatment arm Measured with a 4 points scale : no reaction, low, moderate and severe reaction At baseline, At Month 2, At Month 4 (if realized)
Secondary Pain evaluation during each treatment Mosby Pain Rating Scale for each treatment arm At baseline, At Month 2, At Month 4 (if realized)
Secondary Change in lesion skin color in each treatment arm Measured with Chroma-Meter CR400 (Konica Minolta), Mean a* value At Baseline, at Month 2, 4, 6,12
Secondary Subject satisfaction level Comparison of each treatment arm using Subject Overall Evolution Scale At Month 6,12
Secondary Change in Life Quality Comparison of Dermatology Life Quality Index At Selection, at Baseline, at Month 2, 4 (if realized), 6,12
Secondary Practitioner's opinion Comparison, for each treatment arm, of comfort of use, practicality, duration of treatment At baseline, At Month 2, At Month 4 (if realized)
Secondary Adverse Events Incidence and severity of adverse effects, for each treatment arm, during the study period At Baseline, At Month 2, 4, 6,12
See also
  Status Clinical Trial Phase
Completed NCT02268474 - Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea N/A
Completed NCT00989014 - Dose-Finding Study of CD07805/47 Topical Gel in Subjects With Erythematotelangiectatic Rosacea Phase 2
Completed NCT01756027 - Feasibility Study: Ulthera System for the Treatment of Rosacea N/A
Completed NCT06331533 - Intradermal BoNT-A Treatment in Erythematotelangiectatic Rosacea Phase 4
Completed NCT02144181 - Ultherapy® for the Treatment of Erythematotelangiectatic Rosacea N/A
Recruiting NCT05360251 - Pulsed Dye Laser and Intense Pulsed Light Configured With Different Wavelength Bands in Improving Erythematotelangiectatic Rosacea N/A
Completed NCT01045551 - Open Label Pilot Study of Apremilast in Treatment of Rosacea Phase 2
Completed NCT00945373 - Combination Therapy for the Treatment of Rosacea Phase 1
Completed NCT04153188 - Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride (HCL) 1% Cream for Erythematotelangiectatic Rosacea Phase 4
Completed NCT02393937 - A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea Phase 3
Completed NCT02052999 - Study to Evaluate the Efficacy and Safety of PAC-14028 Cream in Rosacea Patients Phase 2